HEALTH PLAN AND INDUSTRY- NEW PARTNERSHIP TO ASSESS NEW TECHNOLOGY OUTCOMES AND ECONOMIC IMPACT

Author(s)

Marcos Davi Pedra Hume, MSB, Health Economics & Reimbursement Manager1, José Antonio Diniz De Oliveira, BBA, Director, Health Plans and Client Relationship2, Alba Valéria Fleury, MD, Executive Manager, Health Plans2, Ernesto de Matos Nogueira, MBA, Health Economics & Reimbursement Specialist11Johnson & Johnson Medical Brasil, São Paulo, SP, Brazil; 2 Cassi, Brasília, DF, Brazil

Organization: Cassi Problem or Issue Addressed: With the fast pace of new medical technologies launched into the market, it is imperative to develop a formal and methodical approach to assess and evaluate outcomes and impacts; one that goes beyond the short-term vision of price and volume negotiation. Although there are several agencies across the globe that evaluate technologies, not always the market can count on their results because 1) either these reports are based on scenarios that don't reflect the real situation (for instance, a health plan in Africa considering a report about the U.S. medical system); or 2) there is not enough time to wait for a conclusion. Goals: Effective coverage and Reimbursement decisions must reflect the local scenarios where they happen, and new methods to evaluate medical technologies must be in place to allow distant markets to reach their own conclusions about health care. One proposed answer to this problem is to bring different market stakeholders to teamwork and develop an approach that combines everyone's expertise into an effective methodology reflecting the local market scenario and population. In summary, to develop a Health Technology Assessment that reflects the local health care scenario and that is agile enough for a Health Plan. Outcomes items used in the decision: Cost-effectiveness data (literature and local), local prevalence and incidence disease rates. Implementation Strategy: Presentation and validation of methodology to Cassi and J&J Executive Board. Communication of new HTA process to all Cassi's franchises and J&J divisions in Brazil. Results: Work in Progress. One technology assessed, another in evaluation. Cassi hopes to decrease medical costs and improve health care outcomes in 2008. J&J hopes to improve negotiations with Cassi. Lessons Learned: Developing nations cannot count solely on studies performed in developed countries; they must develop analyses that reflect local scenarios and markets. To improve value for patients, one stakeholder cannot act alone. All participants must take action to improve the health care system's efficiency.

Conference/Value in Health Info

2008-05, ISPOR 2008, Toronto, Ontario, Canada

Value in Health, Vol. 11, No. 3 (May/June 2008)

Code

PCASE4

Topic

Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×